Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RNAC
stocks logo

RNAC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
100.22K
-113.2%
-0.866
+45.88%
125.00K
-88.64%
-0.860
+32.31%
125.00K
-58.05%
-0.834
-266.8%
Estimates Revision
The market is revising Upward the revenue expectations for Cartesian Therapeutics, Inc. (RNAC) for FY2025, with the revenue forecasts being adjusted by 4.56% over the past three months. During the same period, the stock price has changed by -35.15%.
Revenue Estimates for FY2025
Revise Upward
up Image
+4.56%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+19.83%
In Past 3 Month
Stock Price
Go Down
down Image
-35.15%
In Past 3 Month
Wall Street analysts forecast RNAC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNAC is 33.50 USD with a low forecast of 16.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast RNAC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNAC is 33.50 USD with a low forecast of 16.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 6.900
sliders
Low
16.00
Averages
33.50
High
40.00
Current: 6.900
sliders
Low
16.00
Averages
33.50
High
40.00
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$40 -> $30
2025-11-19
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$40 -> $30
2025-11-19
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Cartesian Therapeutics to $30 from $40 and keeps a Buy rating on the shares. The firm says Cartesian one of the most "mispriced assets" it has "seen in years." It is "highly unusual for a registration-aligned Phase 3 program with high likelihood of approvability to trade" at a $50M enterprise value, the analyst tells investors in a research note. H.C. Wainwright says that with 100,000 myasthenia gravis patients in the domestic population and a market "rapidly shifting to immunology agents that offer durable disease control," it sees Cartesian's current valuation as "disproportionate to the commercial opportunity and the degree of clinical risk-mitigation."
BTIG
Buy
maintain
$42 -> $44
2025-11-14
Reason
BTIG
Price Target
$42 -> $44
2025-11-14
maintain
Buy
Reason
BTIG raised the firm's price target on Cartesian Therapeutics to $44 from $42 and keeps a Buy rating on the shares. The firm cites the company's positive results disclosed from the Phase 2 trial of Descartes-08 in systemic lupus erythematosus, or SLE, showing a 100% lupus low disease activity state response and 67% disease remission, the analyst tells investors in a research note. Following these Phase 2 results, the company plans to pause development of Descartes-08 in SLE and shift focus to initiating a Phase 2 trial in myositis, with strong mechanistic alignment based on SLE and MG clinical data, the firm added.
Wedbush
NULL -> Outperform
initiated
$38
2025-07-09
Reason
Wedbush
Price Target
$38
2025-07-09
initiated
NULL -> Outperform
Reason
Wedbush initiated coverage of Cartesian Therapeutics with an Outperform rating and $38 price target.
Wedbush
Outperform
initiated
$38
2025-07-09
Reason
Wedbush
Price Target
$38
2025-07-09
initiated
Outperform
Reason
As previously reported, Wedbush initiated coverage of Cartesian Therapeutics with an Outperform rating and $38 price target. With no conditioning requirement, re-dosing capabilities, and an ongoing Phase 3 trial, the firm believes Cartesian Therapeutics could be the first cell therapy company to achieve widespread use in autoimmune diseases. Wedbush notes that a Phase 2 trial in myasthenia gravis yielded deeper responses than benchmarks for approved biologics, and a registrational Phase 3 trial is enrolling. Further upside is possible from expansion into other autoimmune indications. A Phase 2 trial in lupus will have initial data in the second half of 2025, while a Phase 2 pediatric basket trial is enrolling across multiple indications.
Mizuho
Mizuho
Outperform
maintain
$40
2025-05-12
Reason
Mizuho
Mizuho
Price Target
$40
2025-05-12
maintain
Outperform
Reason
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Reiterates
$40
2025-04-09
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$40
2025-04-09
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Cartesian Therapeutics Inc (RNAC.O) is -2.02, compared to its 5-year average forward P/E of -5.67. For a more detailed relative valuation and DCF analysis to assess Cartesian Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.67
Current PE
-2.02
Overvalued PE
-0.89
Undervalued PE
-10.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.29
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.06
Undervalued EV/EBITDA
-3.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
158.35
Current PS
0.00
Overvalued PS
353.87
Undervalued PS
-37.17
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

RNAC News & Events

Events Timeline

(ET)
2025-11-13
16:55:21
Cartesian Reports Encouraging Initial Results from Phase 2 SLE Trial of Descartes-08
select
2025-11-06 (ET)
2025-11-06
07:05:06
Cartesian Therapeutics announces Q3 earnings per share of $1.38, compared to $1.13 in the previous year.
select
2025-10-30 (ET)
2025-10-30
07:20:10
Cartesian Therapeutics reveals new employment incentive grant
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-19Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for Cartesian Therapeutics, Adjusts Price Target to $30

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: Benzinga Pro is designed to help traders win in the markets every day with accurate stock market intelligence.

[object Object]
Preview
9.0
11-15Benzinga
Cartesian Halts Lupus and Multiple Myeloma Research to Redirect Development Efforts

  • Initial Trial Results: Cartesian Therapeutics reported promising initial data from its Phase 2 trial of Descartes-08 for systemic lupus erythematosus (SLE), showing significant disease activity reduction and remission in 2 out of 3 participants at the 3-month follow-up.

  • Shift in Focus: The company plans to pause further development of Descartes-08 in SLE to prioritize its myasthenia gravis and myositis programs, with plans to initiate a new clinical trial for myositis in 2026.

  • Additional Trial Updates: Cartesian also shared results from a Phase 1 trial of Descartes-15 for multiple myeloma, reporting no significant adverse events, but has decided to pause its development to focus on Descartes-08.

  • Financial Outlook: Following the pauses in development, Cartesian expects its current cash resources to support operations through mid-2027, with RNAC stock showing a 4.91% increase.

[object Object]
Preview
6.0
11-14Benzinga
Nvidia Set for Potential 18% Surge? Check Out 10 Leading Analyst Predictions for Friday

  • Analyst Upgrades: Susquehanna raised the price target for Nu Holdings from $17 to $19, while Loop Capital upgraded Shake Shack from Hold to Buy, increasing its target from $98 to $127.

  • Analyst Downgrades: Stifel cut Lowe’s price target from $275 to $230, and Mizuho reduced Applied Materials' target from $215 to $205, maintaining Neutral and Hold ratings respectively.

  • Mixed Ratings: Oppenheimer raised ORIC Pharmaceuticals' target from $12 to $15 with an Outperform rating, while HC Wainwright cut Sanara Medtech's target from $54 to $36 but maintained a Buy rating.

  • Other Notable Changes: Morgan Stanley increased NVIDIA's target from $210 to $220, and Jefferies raised Gap Inc's target from $22 to $30, upgrading it from Hold to Buy.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cartesian Therapeutics Inc (RNAC) stock price today?

The current price of RNAC is 6.9 USD — it has increased 3.76 % in the last trading day.

arrow icon

What is Cartesian Therapeutics Inc (RNAC)'s business?

Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.

arrow icon

What is the price predicton of RNAC Stock?

Wall Street analysts forecast RNAC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNAC is 33.50 USD with a low forecast of 16.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cartesian Therapeutics Inc (RNAC)'s revenue for the last quarter?

Cartesian Therapeutics Inc revenue for the last quarter amounts to 452.00K USD, increased 16.80 % YoY.

arrow icon

What is Cartesian Therapeutics Inc (RNAC)'s earnings per share (EPS) for the last quarter?

Cartesian Therapeutics Inc. EPS for the last quarter amounts to -1.38 USD, increased 22.12 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cartesian Therapeutics Inc (RNAC)'s fundamentals?

The market is revising Upward the revenue expectations for Cartesian Therapeutics, Inc. (RNAC) for FY2025, with the revenue forecasts being adjusted by 4.56% over the past three months. During the same period, the stock price has changed by -35.15%.
arrow icon

How many employees does Cartesian Therapeutics Inc (RNAC). have?

Cartesian Therapeutics Inc (RNAC) has 66 emplpoyees as of December 05 2025.

arrow icon

What is Cartesian Therapeutics Inc (RNAC) market cap?

Today RNAC has the market capitalization of 179.42M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free